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InﬂammationAlthough in vitro studies have shown that nicotinic acid inhibits some aspects of the inﬂammatory response,
a reduced number of in vivo studies have investigated this activity. To the best of our knowledge, the effects
induced by nicotinic acid in models of nociceptive and inﬂammatory pain are not known. Per os (p.o.) admin-
istration of nicotinic acid (250, 500 or 1000 mg/kg,−1 h) inhibited the ﬁrst and the second phases of the no-
ciceptive response induced by formalin in mice. Nicotinic acid (250 or 500 mg/kg,−1 and 3 h) also inhibited
the mechanical allodynia induced by carrageenan in rats, a model of inﬂammatory pain. However, in a model
of nociceptive pain, exposure of mice to a hot-plate, nicotinic acid was devoid of activity. In addition to inhi-
biting the nociceptive response in models of inﬂammatory pain, nicotinic acid (250 or 500 mg/kg, p.o., −1
and 3 h) inhibited paw edema induced by carrageenan in mice and rats. Picolinic acid (62.5 or 125 mg/kg,
p.o., −1 h), a nicotinic acid isomer, inhibited both phases of the nociceptive response induced by formalin,
but not paw edema induced by carrageenan in mice. The other nicotinic acid isomer, isonicotinic acid, was
devoid of activity in these two models. In conclusion, our results represent the ﬁrst demonstration of the ac-
tivity of nicotinic acid in experimental models of nociceptive and inﬂammatory pain and also provide further
support to its anti-inﬂammatory activity. It is unlikely that conversion to nicotinamide represents an impor-
tant mechanism to explain the antinociceptive and anti-inﬂammatory activities of nicotinic acid. The demon-
stration of new activities of nicotinic acid, a drug that has already been approved for clinical use and presents
a positive safety record, may contribute to raise the interest in conducting clinical trials to investigate its use-
fulness in the treatment of painful and inﬂammatory diseases.
© 2012 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction
Nicotinic acid, a member of the vitamin B family, was identiﬁed as
the precursor in the synthesis of nicotinamide adenine dinucleotide
(NAD+) and its analog nicotinamide adenine dinucleotide phos-
phate (NADP+) (Ijichi et al., 1966). These coenzymes participate in
several metabolic pathways and cell signaling (Bogan and Brenner,
2008; Pollak et al., 2007). In addition to being a nutrient, Altschul
et al. (1955) demonstrated that high doses of nicotinic acid decrease
plasma concentrations of cholesterol. Nicotinic acid is the oldest
drug used in the treatment of dyslipidemia and induces favorable
changes in some lipid parameters: reduction of the concentrations
of total cholesterol, triglycerides, very low density lipoprotein, low
density lipoprotein and increase of the concentration of high density
lipoprotein (Carlson, 2005; Wierzbicki, 2011).
In addition to inducing favorable changes in lipid metabolism, nic-
otinic acid exhibits antioxidant and anti-inﬂammatory properties thatCoelho).
ier OA license.may also contribute to its efﬁcacy in the treatment of atherosclerotic
cardiovascular disease (Tavintharan et al., 2011). Nicotinic acid in-
hibits the production of reactive oxygen species and inﬂammatory
mediators induced by different stimuli in cultured human endothelial
cells (Ganji et al., 2009; Tavintharan et al., 2009). These mediators
promote chemotaxis and adhesion of monocytes involved in the for-
mation of the atherosclerotic plaque. Ganji et al. (2009) also showed
that nicotinic acid inhibits low density lipoprotein oxidation and in-
creases the concentrations of NADPH and glutathione, which inhibit
the production of free radicals. Moreover, it has been shown that nic-
otinic acid inhibits the production of atherogenic chemokines and
upregulates the atheroprotective adiponectin in adipocytes (Digby
et al., 2010).
Although many in vitro studies have provided results showing
that nicotinic acid inhibits some aspects of the inﬂammatory response
independently of its effects on lipid metabolism, few in vivo studies
have been carried out to investigate this property. Wang et al.
(1990) showed that nicotinic acid attenuates bleomycin-induced ac-
cumulation of inﬂammatory cells in the lungs of hamsters. In addi-
tion, it has been shown that nicotinic acid markedly attenuates
NFκB activation and inﬂammatory cytokine gene expression in lung
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damage and improves survival (Kwon et al., 2011).
To the best of our knowledge, the effects induced by nicotinic acid
in models of nociceptive and inﬂammatory pain have not been inves-
tigated. Evaluating the effects induced by nicotinic acid in experi-
mental models of pain and inﬂammation is warranted as there is
evidence from in vitro studies indicating that this drug also presents
anti-inﬂammatory activity (Digby et al., 2010; Ganji et al., 2009). In
addition, studies aiming to reposition existing drugs for new indica-
tions is a widely justiﬁed trend that is increasing steadily in recent
years (Ashburn and Thor, 2004) and it has been shown that many
drugs that were originally approved for the treatment of patients
with dyslipidemias exhibit anti-inﬂammatory and antinociceptive
activities (Barsante et al., 2005; Garcia et al., 2011; Oliveira et al.,
2007).
We have recently demonstrated the antinociceptive and anti-
inﬂammatory activities of nicotinamide in such models (Godin et
al., 2011). As nicotinic acid may be converted to nicotinamide in
vivo (Collins and Chaykin, 1972; Petrack et al., 1966), it would be in-
teresting to investigate whether both compounds share these activi-
ties and thus provide information that could contribute to expand
their use in the treatment of painful or inﬂammatory conditions. Re-
garding the nicotinic acid isomers, picolinic and isonicotinic acids,
Heyliger et al. (1998) showed that systemic administration of picoli-
nic acid in mice induces antinociceptive effect in experimental
models of thermal nociceptive pain. Similarly to the experimental ap-
proach we used in our previous study (Godin et al., 2011), we also in-
vestigated the effects induced by nicotinic acid isomers, picolinic and
isonicotinic acids (Fig. 1), to establish whether the change of the lat-
eral chain position in the pyridine ring could result in compounds
with different activities.
2. Materials and methods
2.1. Animals
Female Swiss mice (24–28 g) and Wistar rats (200–250 g) were
used and had free access to food and water. The animals were kept
in a room with 12 h light–dark cycle and temperature of 27 °C,
which corresponds to the thermoneutral zone for rodents, for at
least 3 days before the experiment to allow acclimatization. The tem-
perature of 27 °C was used because the thermoneutral zone for mice
and rats ranges between 26 and 34 °C, temperatures that markedly
differ from that of standard laboratory environments which could
be stressful and affect many aspects of physiology and behavior
(Gaskill et al., 2009; Gordon, 1990). All experiments were approved
by the Ethics Committee on Animal Experimentation of the Federal
University of Minas Gerais and carried out according to the ethical
guidelines for investigation of experimental pain in conscious animals
(Zimmermann, 1983).
2.2. Drugs
Suspensions of nicotinic acid (Sigma, USA), isonicotinic acid
(Sigma-Aldrich, Germany), picolinic acid (Sigma-Aldrich, Germany),Fig. 1. Chemical structures of nicotinic acid and its isomers, picolinic and isonicotinic
acids.dexamethasone 21-phosphate disodium salt (Sigma, USA), dipyrone
(Sanoﬁ Aventis, Brazil) and phenobarbital (Aventis Pharma, Brasil)
were prepared in 0.5% carboxymethylcellulose sodium salt (Sigma,
USA) suspension in saline immediately before the experiments.
Suspensions were administered per os (p.o.) in a volume of 12 ml/kg.
λ–carrageenan (Sigma, USA) suspension and formaldehyde (Sigma,
USA) solution were prepared in saline.
2.3. Evaluation of the nociceptive response induced by formalin in mice
One hour after p.o. administration of nicotinic, isonicotinic or pico-
linic acids, a volume of 20 μl of formalin (2.5%, corresponding to 0.92%
formaldehyde) was injected via the subcutaneous (s.c.) route into the
dorsum of the right hind paw. Each mouse was placed under a trans-
parent glass funnel (18 cm diameter, 15 cm-high) and the amount of
time that the animal licked the injected paw was determined be-
tween 0 and 5 min (ﬁrst phase) and 15 and 30 min (second phase)
after the injection of formalin.
2.4. Evaluation of the nociceptive response of mice in the hot-plate model
We selected the plate temperature of 50 °C to evaluate the effect
induced by nicotinic acid in this model of nociceptive pain. This tem-
perature was chosen as a higher temperature (54 °C) reduces the
probability of detecting an antinociceptive effect in this experimental
model (Godin et al., 2011). One hour after treatment with nicotinic
acid or dipyrone (positive control), each animal was placed on the
hot-plate. The latency to lick one of the hind paws or to jump off
the plate was determined. The animal was removed from the hot-
plate immediately after the response. The cut-off time was 50 s to
avoid tissue damage.
2.5. Evaluation of the edema induced by carrageenan in rats or mice
A plethysmometer (Model 7140, Ugo Basile, Italy) was used to
measure paw volume. Before administration of any drug, the basal
volume of the right hind paw was measured. After determination of
the basal paw volume, the animals were divided into the experimen-
tal groups in such a way that the mean volumes of the different
groups were similar. Carrageenan was injected via the intraplantar
(i.pl.) route in rats (500 μg, 50 μl) or mice (600 μg, 30 μl). Considering
that (a) the paw volume was measured at 2, 4 and 6 h later, (b) the
half-life of nicotinic acid is about 1 h (Petrack et al., 1966) and (c)
preliminary results indicated that only one dose of nicotinic acid did
not markedly inhibit the response evaluated, we administered two
doses of nicotinic acid, 1 h before and 3 h after carrageenan. Similar
protocol was used for isonicotinic and picolinic acids. The results
were presented as the paw volume changes in relation to the basal
values.
2.6. Evaluation of mechanical allodynia induced by carrageenan in rats
Mechanical allodynia was measured with a 40 mN nylon ﬁlament
(Sorri, Brazil) as previously described (Souza et al., 2002). Brieﬂy, the
rats were kept individually in Perspex boxes (20×20 cm with 18 cm-
high walls) whose ﬂoor was a metal grid through which the ﬁlament
was pressed on the plantar surface of the right hind paw with the
strength just necessary to cause it to bend for approximately 1 s. The
number of withdrawal reﬂexes was determined in a trial of 10 touches
for each rat. The basal withdrawal frequency was determined before
administration of any drug. Once the basal withdrawal frequency was
determined, the animals were divided into the experimental groups
in such a way that the mean withdrawal frequencies of the different
groups were similar. The withdrawal frequency was determined at 2,
4 and 6 h after injection of the inﬂammatory stimulus. Nicotinic acid
was administered 1 h before and 3 h after carrageenan.
Fig. 2. Effect induced by nicotinic acid (250, 500 or 1000 mg/kg, p.o.,−1 h) on the no-
ciceptive response induced by formalin (2.5%; 20 μl; s.c.) in mice. *, ** and *** signiﬁ-
cantly different from vehicle (pb0.05, pb0.01 and pb0.001, respectively). n=8.
Fig. 4. Effect induced by nicotinic acid (250 or 500 mg/kg, p.o., −1 h and 3 h) on the
mechanical allodynia induced by carrageenan (500 μg, 50 μl, i.pl.) in rats. *** signiﬁ-
cantly different from vehicle (pb0.001). n=8.
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A rota-rod apparatus was used to evaluate the motor activity of the
animals. The animals were trained on the apparatus for 3 days before
the experiment. On the experimental day, the animals were placed on
the rota-rod (14 rpm) and the time they spent on it was measured.
The cut-off time was 2 min. After determination of the baseline values,
the animals were treated with nicotinic or picolinic acids or phenobar-
bital (positive control) and 1 h later they were again tested in the appa-
ratus. In another protocol, we evaluated the effect induced by two
administrations of nicotinic acid to validate the results observed in the
model ofmechanical allodynia. The ﬁrst administration occurred 3 h be-
fore theﬁrst evaluation of themotor activity. The second administration
occurred 1 h after theﬁrst evaluation of themotor activity. After the sec-
ond administration, the motor activity was evaluated at 1 and 3 h.
2.8. Data collection and statistical analysis
Two observers evaluated the nociceptive behavior and edema in
the different experimental protocols. The observers were not aware
of the treatments and registered the nociceptive behavior or edema
of animals from the different experimental groups within each proto-
col. The results were presented as mean±standard error mean
(S.E.M.) and analyzed by one-way analysis of variance followed by
Newman–Keuls post-hoc test when the main effect was signiﬁcant.
A Pb0.05 was considered signiﬁcant. Statistical analysis was con-
ducted using GraphPrism 5.0 for Windows.
3. Results
Nicotinic acid, at the doses of 250, 500 or 1000 mg/kg, inhibited
both phases of the nociceptive response induced by formalin in mice
(Fig. 2). As the doses of 500 and 1000 mg/kg induced similar effects,
we chose the doses of 250 or 500 mg/kg for subsequent experiments.
Nicotinic acid (250 or 500 mg/kg) did not increase the latency for theFig. 3. Effect induced by nicotinic acid (250 or 500 mg/kg, p.o., −1 h) or dipyrone
(500 mg/kg, p.o., −1 h) on the nociceptive response induced by heat (hot plate
model, 50 °C). *** Signiﬁcantly different from vehicle (pb0.001). n=10.nociceptive response of mice in the hot-plate model (Fig. 3). However,
the latency for the nociceptive response was increased after treatment
of the animals with dipyrone (500 mg/kg). Nicotinic acid (250 or
500 mg/kg) also inhibited the mechanical allodynia induced by carra-
geenan in rats (Fig. 4).
To validate the results observed in the nociceptive models, we in-
vestigated the effects induced by nicotinic acid on the motor coordi-
nation of the animals. Single (−1 h) or double (−1 h and 3 h) doses
of nicotinic acid (500 mg/kg) did not alter the time mice spent in the
rota-rod apparatus. The positive control, phenobarbital (50 mg/kg)
markedly inhibited the performance of the animals (Table 1).
In addition to inhibiting the nociceptive response, nicotinic acid
(250 or 500 mg/kg) also inhibited the paw edema induced by Carra-
geenan inmice (Fig. 5). Aiming to verifywhether this inhibition also oc-
curs in other species, we observed that nicotinamide (250 or 500 mg/
kg) also reduces the inﬂammatory edema in rats (Fig. 6). In both spe-
cies, the inhibitory effect induced by nicotinic acid on carrageenan-
induced edema was more marked on the late phase of the response.
Next, we investigated whether the nicotinic acid isomers, isoni-
cotinic and picolinic acids, also exhibit similar activities. Isonicotinic
acid (250 or 500 mg/kg) did not inhibit the nociceptive response in-
duced by formalin in mice (Fig. 7). However, when we evaluated the
effects induced by picolinic acid (250 or 500 mg/kg), we observed
lethality similarly to what was observed for picolinamide in our pre-
vious study (Godin et al., 2011). Therefore, the doses were reduced
to 62.5 or 125 mg/kg. Information in the literature about the lethal
dose of the picolinic acid was not found. Picolinic acid (125 mg/
kg) inhibited both phases of the nociceptive response induced by
formalin in mice (Fig. 8).
To validate the antinociceptive activity of picolinic acid, we investi-
gated its effect on the motor coordination of mice. Picolinic acid
(125 mg/kg) did not alter the timemice spent in the rota-rod apparatus
(Table 1).Table 1
Effect induced by nicotinic acid (500 mg/kg, p.o.,−1 h or−1 h and 3 h), picolinic acid
(125 mg/kg, p.o., −1 h) or phenobarbital (50 mg/kg, p.o., −1 h) on the time spent by
mice on the rota-rod.
Treatment Time spent on the rotating rod (s)
Baseline 1 h
Vehicle 120±0 119±1
Nicotinic acid 500 120±0 120±0
Picolinic acid 125 120±0 120±0
Phenobarbital 50 120±0 14±2a
Baseline 2 h 4 h 6 h
Vehicle 119±1 120±0 119±1 120±0
Nicotinic acid 500 120±0 120±0 120±0 120±0
a Signiﬁcantly different from respective vehicle-treated group at the same time point
(Pb0.001). n=8.
Fig. 5. Effect induced by nicotinic acid (250 or 500 mg/kg, p.o., −1 h and 3 h) on the
edema induced by carrageenan in mice. The mean basal paw volumes of the groups
treated with vehicle, nicotinic acid 250 and nicotinic acid 500 were 114±2, 111±2
and 113±2 μl, respectively. * and ** signiﬁcantly different from vehicle (pb0.05 and
pb0.01, respectively). n=8.
Fig. 7. Effect induced by isonicotinic acid (250 or 500 mg/kg, p.o., −1 h) on the noci-
ceptive response induced by formalin (2.5%; 20 μl; s.c.) in mice. n=8.
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picolinic acids on the nociceptive response induced by formalin, we
evaluated their effects in a model of inﬂammatory edema in mice.
These compounds did not inhibit the paw edema induced by Carra-
geenan. The positive control, dexamethasone (10 mg/kg), markedly
inhibited the paw edema at 2, 4 and 6 h (Figs. 9 and 10).4. Discussion
Initially, we investigated the effect induced by nicotinic acid in the
model of nociceptive response induced by formalin in mice. Widely
used, this is an experimental model of continuous pain that results
from tissue injury and consequent inﬂammation and also activation
by formaldehyde of transient receptor potential (TRP) channels, specif-
ically TRPA1 (McNamara et al., 2007) and TRPV1 (Tian et al., 2009), in
nociceptors. The formalin pain model is useful to screen candidates for
analgesic compounds as it encompasses inﬂammatory, neurogenic and
central mechanisms of nociception (Tjolsen et al., 1992). Although nic-
otinic acid inhibited both phases of the nociceptive response induced
by formalin, the second phase was inhibited to a greater extent indicat-
ing a proﬁle similar to that of anti-inﬂammatory drugs (Hunskaar and
Hole, 1987). The anti-inﬂammatory proﬁle was further supported by
the inhibition of the mechanical allodynia and edema induced by i.pl.
injection of carrageenan, responses that result from the local produc-
tion of a variety of inﬂammatory mediators (Cunha et al., 2000;
Handy and Moore, 1998; Salvemini et al., 1996; Vinegar et al., 1987),
and lack of effect on the nociceptive response induced by heat in the
hot-plate model, an immediate response due to direct activation of
heat-sensitive channels of the TRP family (Vriens et al., 2011).Fig. 6. Effect induced by nicotinic acid (250 or 500 mg/kg, p.o., −1 h and 3 h) on the
edema induced by carrageenan in rats. The mean basal paw volumes of the groups trea-
ted with vehicle, nicotinic acid 250 and nicotinic acid 500 were 1.17±0.07, 1.18±0.05
and 1.18±0.04 ml, respectively. * and ** signiﬁcantly different from vehicle (pb0.05
and pb0.01, respectively). n=6.Regarding the inhibition induced by nicotinic acid on the noci-
ceptive behavior in the experimental models of pain, it is highly un-
likely that it is the result of motor incoordination or muscle relaxing
effect, as the time that the animals spent in the rota-rod was not al-
tered. Such validation is important as it has been demonstrated that
nicotinic acid inhibits seizures induced by pentylenetetrazole or
kynurenine, suggesting a central depressant effect (Lapin, 1981).
The mechanisms that contribute to the anti-inﬂammatory proﬁle
of nicotinic acid in the experimental models of inﬂammatory pain
and edema are not clear. However, it has been shown that nicotinic
acid decreases the activation of NF-κB (Crowley et al., 2000; Ganji et
al., 2009; Kwon et al., 2011; Tavintharan et al., 2009), a transcription
factor that regulates the production of many inﬂammatory mediators
(Lawrence, 2009; Lentsch and Ward, 1999) that are clearly involved
in the nociceptive response induced by formalin (Chichorro et al.,
2004; Tjolsen et al., 1992) and in the allodynia and edema induced
by carrageenan (Chen et al., 1994; Nakamura et al., 1996; Salvemini
et al., 1996; Tonussi and Ferreira, 1994). Importantly, many inﬂam-
matory stimuli activate NF-κB (Sum and Anderson, 2002) and it has
been recently demonstrated that transgenic mice that overexpress a
protein (IκB) that inhibits the NF-κB pathway exhibit a reduced noci-
ceptive response induced by formalin (Fu et al., 2007). Moreover, the
ﬁrst and second phases of the nociceptive response induced by for-
malin are inhibited in NF-κB-deﬁcient mice (Niederberger et al.,
2007). More direct evidence that nicotinic acid may inhibit the pro-
duction of inﬂammatory cytokines was recently provided by Kwon
et al. (2011) who demonstrated that high doses of this compound re-
duce the serum concentrations of tumor necrosis factor (TNF)-α and
interleukin (IL)-6 in endotoxemic rats.
Recently, it has been shown that nicotinic acid is a ligand to
GPR109A receptor, a member of G-protein-coupled receptors that
are targets for endogenous hydroxy-carboxylic acid metabolites (for
a review see Offermanns et al., 2011; Tunaru et al., 2003). The
GPR109A was initially identiﬁed in adipocytes and its role in the me-
diation of the anti-lipolytic and lipid-lowering effects of nicotinic acid
in vivo was demonstrated (Tunaru et al., 2003). Additional studiesFig. 8. Effect induced by picolinic acid (62.5 or 125 mg/kg, p.o.,−1 h) on the nociceptive
response induced by formalin (2.5%; 20 μl; s.c.) in mice. * and ** signiﬁcantly different
from vehicle (pb0.05 and pb0.01, respectively). n=8.
Fig. 9. Effect induced by isonicotinic acid (250 or 500 mg/kg, p.o.,−1 h and 3 h) on the
edema induced by carrageenan in mice. The mean basal paw volumes of the groups
treated with vehicle, isonicotinic acid 250, isonicotinic acid 500 and dexamethasone
10 were 94±3, 95±5, 97±4 e 93±5 μl, respectively. * signiﬁcantly different from
vehicle (pb0.05). n=8.
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neutrophils (Knowles et al., 2006; Kostylina et al., 2008), cells that
have important roles in many aspects of the inﬂammatory response.
However, the role of GPR109A in mediating the antinociceptive and
anti-inﬂammatory activities of nicotinic acid has not been objectively
investigated as antagonists for this receptor or GPR109A deﬁcient an-
imals are still not available.
As nicotinic acid may be converted to nicotinamide (Collins and
Chaykin, 1972; Petrack et al., 1966), a compound that induces marked
effects in experimental models of nociceptive and inﬂammatory pain
(Godin et al., 2011), it could be suggested that such conversion could
play an important role in the antinociceptive and anti-inﬂammatory
activities of nicotinic acid. However, if such conversion plays a role, it
is minor, as the doses of nicotinamide that induce antinociceptive
and anti-inﬂammatory effects in the experimental models used in our
studies are higher than those of nicotinic acid. In the formalin model,
nicotinic acid at the dose of 250 mg/kgmarkedly inhibited the nocicep-
tive response (present study), while a dose of 500 mg/kg of nicotin-
amide was ineffective (Godin et al., 2011).
The evaluation of the effects induced by the isomers of nicotinic
acid on the nociceptive response induced by formalin and the paw
edema induced by carrageenan demonstrated how the position of
the acid side chain attached to the pyridine ring can inﬂuence the ac-
tivities of the nicotinic acid isomers. Physical–chemical analysis dem-
onstrated that these isomers differ in their steric and electrostatic
interactions (Seliger et al., 2006) which may contribute to different
biological activities, such as the lethality induced by higher doses of
picolinic acid, the isomer that possess the side chain in the ortho po-
sition of pyridine ring, and the lack of activity of isonicotinic acid, the
isomer that possess the side chain in the para position of pyridineFig. 10. Effect induced by picolinic acid (62.5 or 125 mg/kg, p.o.,−1 h and 3 h) on the
edema induced by carrageenan in mice. The mean basal paw volumes of the groups
treated with vehicle, picolinic acid 62.5, picolinic acid 125 and dexamethasone 10
were 106±3, 104±3, 105±2, 107±4 μl, respectively. * and ** signiﬁcantly different
from vehicle (pb0.05 and pb0.01, respectively). n=8.ring, in the models of nociceptive response induced by formalin and
paw edema induced by carrageenan.
If the side chain in the para position of the pyridine ring (isonico-
tinic acid) leads to the loss of antinociceptive and anti-inﬂammatory
activities, the side chain in the ortho position (picolinic acid) results
in a drug with a different proﬁle. Picolinic acid inhibited both the
ﬁrst and second phases of the nociceptive response induced by for-
malin, an activity that was not associated with motor incoordination.
Our results do not represent the ﬁrst demonstration of the antinoci-
ceptive activity of picolinic acid. Heyliger et al. (1998) had already
demonstrated that picolinic acid induces antinociceptive effect in
the hot-plate and tail ﬂick models. As picolinic acid did not inhibit
paw edema induced by carrageenan, it is possible that its antinocicep-
tive activity is associated mainly with the inhibition of nociceptive
processing in the central nervous system. Interestingly, it has been
demonstrated that picolinic acid inhibits the activation of spinal
interneurons induced by glutamate (Tonohiro et al., 1990), an impor-
tant mediator of the spinal nociceptive processing (Bleakman et al.,
2006; Larsson, 2009).
In conclusion, our results represent the ﬁrst demonstration of the
activity of nicotinic acid in different experimental models of nocicep-
tive and inﬂammatory pain and also provide further support to its
anti-inﬂammatory activity. It is highly unlikely that conversion to nic-
otinamide represents an important mechanism to explain the antino-
ciceptive and anti-inﬂammatory activities of nicotinic acid. The acid
side chain in the meta position is important for its activity, as the iso-
mers with the chain in the ortho (picolinic acid) and para (isonicotinic
acid) positions exhibit reduced or absent activity in the experimental
models evaluated. The demonstration of new activities of nicotinic
acid, a drug that has already been approved for clinical use and ex-
hibits a positive safety record, clearly exempliﬁes the importance of
promoting drug repositioning, a strategy that has raised great interest
in the last years due mainly to the sustained high attrition rate and
costs in attempts to bring new drugs to the market. Altogether, the re-
sults may contribute to raise the interest in conducting clinical trials
to investigate the usefulness of nicotinic acid in the treatment of pain-
ful and inﬂammatory diseases.
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